— Latest update: March 2022 —
Japan has the third-largest pharmaceutical market in the world although the changing demographics are creating a challenging business landscape. Because of Japan’s aging population and the falling birthrate and the resulting financial difficulties for Japan’s medical system, the Japanese government has taken various measures to cut healthcare spending, which in turn has led to very complex reimbursement and pricing rules. However, the pharmaceutical sector offers substantial opportunities for growth given Japan's ageing population is likely to increase demand for pharmaceuticals from EU countries.
Which opportunities does the Biopharmaceutical market in Japan offer to EU companies?Among Biotechnology, the field of biopharmaceuticals is a core sector in terms of market size and growth potential
This website and related activities are managed by the EU-Japan Centre for Industrial Cooperation, a joint venture between the European Commission's Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs (DG GROW) and the Japanese Government's Ministry of Economy, Trade & Industry (METI).
No less than 300 web pages with up-to-date information on Japan, more than 170 reports available as well as a lot of detailed information on the Japanese business culture.